KAT2A

Across TCGA pan-cancer cohorts, KAT2A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of KAT2A’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where KAT2A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KAT2A is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LSCC, HNSC, and LUAD are the cancer types where KAT2A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KAT2A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.451	<.001	8	view →
HNSC	All	III,IV	+0.392	<.001	6	view →
LUAD	Male	All	+0.344	<.001	6	view →
PDAC	Female	All	−0.545	.019	2	view →
CCRCC	Female	II,III,IV	+0.195	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

KAT2A–LSCC

Open the LSCC breakdown →